The anti-GM-CSF therapy mavrilimumab was effective in decreasing RA disease activity in a Phase 2b clinical trial, with over 70% of RA patients achieving an ACR20 improvement in the group receiving the highest dosing regime (88). Here, CSF2 is linked to rheumatoid arthritis.